|
Highs and Lows for Roche: Good Perjeta Data, Bad Inspection Report
Roche subsidiary Genentech’s breast cancer treatment Perjeta extended patients’ lives in a key clinical trial — another boost for the drug, which received FDA approval earlier this month.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives